Cell therapy biotech Sana Biotechnology prices further upsized IPO at $25, above the upwardly revised range

Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, raised $588 million by offering 23.5 million shares at $25, above upwardly revised the range of $23 to $24.